What is ALT's current stock price?

ALT (Altimmune, Inc.) is currently trading at $2.90 with a market cap of $255.9M.

What sector is Altimmune, Inc. in?

Altimmune, Inc. (ALT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ALT a good stock to buy?

Analysts have a Buy consensus on ALT with a price target of $11.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ALT Altimmune, Inc.

Healthcare

$2.90-1.02%ClosedMarket Cap: $255.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.27

P/S

7109.62

EV/EBITDA

-2.08

DCF Value

$0.08

FCF Yield

-28.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

-41519.4%

Operating Margin

-269216.7%

Net Margin

-253002.8%

ROE

-42.6%

ROA

-27.1%

ROIC

-29.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-22.6M	$—
Q4 null	$26.0K	$-27.4M	$—
FY null	$41.0K	$-88.1M	$—
Q3 null	$5.0K	$-19.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.25

Target (Median)

$11.25

Target Range

$2.50 - $20.00

3 Strong Buy6 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-18

CitizensMarket Outperform

2026-05-14

HC Wainwright & Co.Buy

2026-03-16

B. Riley SecuritiesBuy

2026-03-06

CitizensMarket Outperform

2025-11-07

Trading Activity

Insider Trades

View All

Sohn Catherine A.director

SellFri May 01

Schafer Klausdirector

SellFri May 01

SAYARE MITCHELdirector

SellFri May 01

Pisano Waynedirector

SellFri May 01

Lawver Teri Ldirector

SellFri May 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.17

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Peers